Contrasting NeuroOne Medical Technologies (NASDAQ:NMTC) and Inari Medical (NASDAQ:NARI)

NeuroOne Medical Technologies (NASDAQ:NMTC) and Inari Medical (NASDAQ:NARI) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, valuation and analyst recommendations.

Profitability

This table compares NeuroOne Medical Technologies and Inari Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NeuroOne Medical Technologies	-356.76%	-407.04%	-229.19%
Inari Medical	-13.68%	-10.09%	-6.60%

Institutional and Insider Ownership

16.1% of NeuroOne Medical Technologies shares are owned by institutional investors. Comparatively, 91.0% of Inari Medical shares are owned by institutional investors. 7.5% of NeuroOne Medical Technologies shares are owned by company insiders. Comparatively, 10.6% of Inari Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings for NeuroOne Medical Technologies and Inari Medical, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroOne Medical Technologies	0	0	0	0	0.00
Inari Medical	0	12	2	0	2.14

Inari Medical has a consensus price target of $68.00, indicating a potential downside of 14.52%. Given Inari Medical’s stronger consensus rating and higher probable upside, analysts plainly believe Inari Medical is more favorable than NeuroOne Medical Technologies.

Earnings & Valuation

This table compares NeuroOne Medical Technologies and Inari Medical”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroOne Medical Technologies	$3.45 million	9.39	-$12.32 million	($0.46)	-2.28
Inari Medical	$493.63 million	9.43	-$1.64 million	($1.35)	-58.93

Inari Medical has higher revenue and earnings than NeuroOne Medical Technologies. Inari Medical is trading at a lower price-to-earnings ratio than NeuroOne Medical Technologies, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

NeuroOne Medical Technologies has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500. Comparatively, Inari Medical has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500.

Summary

Inari Medical beats NeuroOne Medical Technologies on 12 of the 14 factors compared between the two stocks.

About NeuroOne Medical Technologies

NeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders. It also fucuses on applications for other areas, such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator. The company was incorporated in 2009 and is based in Eden Prairie, Minnesota.

About Inari Medical

Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.